Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Mimrylo / Rusfertide for Polycythemia Vera

As of October 2026, MARA’s assessment finds Mimrylo / Rusfertide’s reimbursement risk concentrated in comparator selection, with care pathway integration a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs resource use and cost implications: what the drug adds to, or removes from, the wider bill beyond its own price — administration, monitoring, hospital time. The strength recorded in care pathway integration carries weight because that domain asks how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny.

Hematology

This rating sits within MARA’s Hematology coverage, alongside 21 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

The VERIFY study showed strong evidence for hematocrit and phlebotomy control with rusfertide, with significant differences in phlebotomy eligibility and hematocrit control compared to placebo. However, it did not establish superiority to active cytoreductive strategies.

Does the economic case hold at the expected price? — Cost effectiveness

No cost-utility analysis, ICER, or economic model was identified for rusfertide. The absence of these data means cost-effectiveness cannot be assessed.

Is there quality-of-life evidence payers weigh? — Quality of life

PROMIS Fatigue Short Form 8a showed a statistically significant improvement, but the magnitude was modest and lacked a trial-specific minimal clinically important difference. No utility values or comprehensive HRQoL data were available.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Common adverse events were well characterized, with manageable injection-site reactions and anemia. Long-term risks remain under study, but no unacceptable safety concerns were identified.

Was the drug compared against what payers expect? — Comparator Selection

The study used placebo as a comparator, which is relevant for assessing add-on efficacy but does not address comparisons with active cytoreductive therapies. This limits the ability to position rusfertide against existing treatments.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trial population was moderately representative of the target population, with reasonable age and thrombotic-risk coverage. However, there were underrepresented racial groups and limited subgroup analysis.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Rusfertide fits well into existing care pathways as an add-on treatment, with straightforward diagnostic integration and monitoring requirements.

Are the wider system costs understood? — Resource Use and Cost Implications

While phlebotomy use was reduced, the overall resource implications, including costs of monitoring and administration, were not fully quantified.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The VERIFY study was well-designed and provided robust evidence for hematocrit control. However, long-term outcomes and active-comparator data were lacking.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

There is high uncertainty regarding long-term outcomes such as thrombosis prevention and transformation. No formal sensitivity analysis was available to address these uncertainties.

Be alerted when this rating changes:

Sample two-page MARA Rating report for the fictional drug Samplinib: page one with the rating, its key numbers and the past decisions on drugs in the same rating band; page two with the ten graded payer-side domains and the reasoning behind each
Every MARA rating is delivered as a two-page reasoned report (sample, fictional product) — see it in full
Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.